Prescient Therapeutics (ASX:PTX) completed the first site initiation visit of its phase 2a clinical study of cancer treatment candidate PTX-100, according to a Wednesday filing with the Australian bourse.

The primary endpoint of the study is efficacy, while secondary endpoints include safety, according to the filing.

The study will evaluate two dosage levels of PTX-100 in about 40 patients with relapsed/refractory cutaneous T-cell lymphoma on an open-label basis, the filing said.

Cutaneous T-cell lymphoma is a rare type of non-Hodgkin lymphoma that affects the skin.

Shares rose nearly 7% in afternoon trade Wednesday.